Last updated on March 2020

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Brief description of study

The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.

Clinical Study Identifier: NCT02754141

Find a site near you

Start Over

Local Institution

Melbourne, Australia
  Connect »